GemVax & KAEL Co.,Ltd. Logo

GemVax & KAEL Co.,Ltd.

Clinical-stage biopharma developing therapeutics for neurodegenerative diseases.

082270 | KO

Overview

Corporate Details

ISIN(s):
KR7082270000
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노11로 58, 대전광역시

Description

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-11-12 00:00
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 49.4 KB
2024-10-24 00:00
투자판단관련주요경영사항(임상시험결과) (진행성 핵상마비 치료제로서 GV1001의 국내 2a상 임상시험 Topline d…
Korean 14.4 KB
2024-10-21 00:00
주식등의대량보유상황보고서(일반)
Korean 153.5 KB
2024-10-15 00:00
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 49.4 KB
2024-10-14 00:00
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 49.0 KB
2024-10-11 00:00
[기재정정]주요사항보고서(신주인수권부사채권발행결정)
Korean 71.8 KB
2024-09-25 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.7 KB
2024-09-25 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.6 KB
2024-09-25 00:00
주식등의대량보유상황보고서(일반)
Korean 174.2 KB
2024-09-25 00:00
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 53.0 KB
2024-09-24 00:00
기업설명회(IR)개최
Korean 6.8 KB
2024-09-24 00:00
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 59.1 KB
2024-09-13 00:00
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 51.2 KB
2024-08-27 00:00
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 51.2 KB
2024-08-20 00:00
주식등의대량보유상황보고서(일반)
Korean 162.4 KB

Automate Your Workflow. Get a real-time feed of all GemVax & KAEL Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GemVax & KAEL Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GemVax & KAEL Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.